Tue, Jan 27, 2015, 4:34 PM EST - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Arena Pharmaceuticals, Inc. Message Board

  • pharmaapproved pharmaapproved Nov 5, 2013 5:42 PM Flag

    I really worry about how much is being spent

    The pipeline, 10% CV study, Pediatric study, Production expenses, higher general expenses and rising salaries? I was just going through the last 10K and they warns us that these are going to be costly, and more then in the past. I hope they are bringing in more then is going out. Of course another partnership of some sort or news on S. Korea, Taiwan or both could be in the cards.

    Before anyone mentions COH. That should be building, not falling.

    Thoughts?

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • The only path forward is a successful product, conserving cash buys nothing.

    • They have $62 million in collaboration and Milestone payments coming between now through 2015. I am using Kolowski's newly revised figures for this. As I previously noted, I believe they also will sign a European partnership agreement at any moment that will bring in another $50 million upfront (same amount Eisai paid upfront for US without any approvals). That's a total of $112 million in new cash coming.

    • 3rd quarter with definitely have the least cash coming in the door. No doubt about it. There will be cash burn. When Eisai paid us for the first batch of Belviq they paid us a higher rate per script than what we are experiencing with the discounts and freebies. Cash from other partnerships, countries and Belviq will start to flow again next quarter. The CV studies and the pediatric studies will not start until early next year. The good news is there is no debt, so no interest expense and no payment of principal to speak of. There was 178 Million in cash at 6/30. It will be down to around 156Million at 9/30. Good news is expenses are reasonably low and the 156 Million will last for some time as sales start to ramp up. They have said they will cut back on R&D if sales do not ramp up so I am not that worried. They will also borrow money before they would do another offering.

      • 3 Replies to sharonconk
      • Sells picking up so is revenue and with addition of 200 sells force the results are inevitably positive. ARNA has nothing to loose and burning cashing cooking drugs in the pipeline and not going for any useless Bonuses. By the end of 2014 ARNA will overpass income over expenditures and more accumulations of cash. Belviq a success not as Spencer Osborn and new Zack's analysis without details.

      • I hear you, but unfortunately this is all speculative or coming way down the rode. I used to be under the impression that the NOVEL pipeline, possibility of future partnership deals, milestones and the ROW would be enough for higher valuation. I guess it was at one time until Lonnol made either a mistake, an assumption or lied, you decide! Anyway there is a lot to fund going forward so the things you speak of need to come soon, very soon!

      • Sharon, your item about United Health Care prior approval coverage disappeared. Was it deleted by Yahoo? I was clicking on it to read and it was suddenly the victim of an "error."

    • It. Is a concern and I have no handle on it other than them saying they are aware of it sharon talk to this issue maybe she can opine

 
ARNA
4.77+0.15(+3.25%)4:00 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.